NCT03328364View on ClinicalTrials.gov

A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden

CompletedOBSERVATIONAL
Enrollment

211

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

December 24, 2017

Study Completion Date

December 24, 2017

Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
DRUG

enzalutamide

oral

DRUG

docetaxel

intravenous infusion

Trial Locations (1)

Unknown

Site SE46001, Malmo

Sponsors
All Listed Sponsors
lead

Astellas Pharma a/s

INDUSTRY

NCT03328364 - A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden | Biotech Hunter | Biotech Hunter